Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma ...

Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...

Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high-risk CSCC in phase 3 trial: Tarrytown, New York Wednesday, January 15, 2025, 11:00 Hrs [IST] ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference. Shares of the company moved up in pre-market trading on Jan. 14.

Regeneron promotes EYLEA, Libtayo, and Dupixent at JPMorgan event while touting a pipeline that targets major disease areas.

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline ...

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in ...

The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...